|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.11.25 - 13:57
|
Medicare Secures 71% Price Cut On Novo′s Anti-Obesity Drug As Part Of Broad Affordability Push (ZeroHedge)
|
|
|
Medicare Secures 71% Price Cut On Novo's Anti-Obesity Drug As Part Of Broad Affordability Push
The Trump administration is laser-focused on "Operation Affordability," aiming to drive down the cost of food and healthcare ahead of the midterm election cycle.
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced a savings of 44%, or $12 billion, from last year's negotiated Medicare spending on 15 drugs used to treat severe chronic conditions and cancer.
Of those price cuts, CMS negotiated a 71% discount on GLP-1 medication, including Ozempic and Wegovy, for Medicare patients.
Other significant reductions include a 50% cut for Pfizer's Ibrance, a 48% drop for the prostate-cancer drug Xtandi, and a 73% reduction for GSK's Trelegy Ellipta.
Here's more from CMS:
The Maximum Fair Prices (MFPs) for these 15 drugs will become effective January 1, 2027, bringing the total number of negotiated drugs to 25 when combined with the 10 previously negotiated drugs with...
|
|
|
|
|
26.11.25 - 09:48
|
Bayer Aktie: Endlich der finale Ausbruch? Chartanalyse (Aktiencheck)
|
|
|
Düsseldorf (www.aktiencheck.de) - Bayer-Chartanalyse von HSBC Trinkaus & Burkhardt:
Die Analysten von HSBC Trinkaus & Burkhard nehmen in einer aktuellen Aktienanalyse die Aktie der Bayer AG (ISIN: DE000BAY0017, WKN: BAY001, Ticker-Symbol: BAYN, NASDAQ OTC-Symbol: BAYZF) charttechnisch unter die Lupe. [mehr]...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
